Damoratx
Founded 2025 · 44 employees on LinkedIn · 1 known investors
Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
Founders & leadership
JJ
Jennifer JarrettChief Executive Officer & Board Director
SS
Sherwin SattarzadehChief Operating Officer
BH
Becker HewesChief Medical Officer
Investors · 1
Frequently asked questions
- What does Damoratx do?
- Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.
- Who are Damoratx's investors?
- Damoratx's investors include TCG Crossover.